Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLight: AZD4512 Monotherapy in Relapsed/Refractory CD22-positive B-cell Acute Lymphoblastic Leukemia
jRCT2031250707Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of AZD4512 in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicities in Module 1 (dose escalation), Safety and tolerability in Module 1 (TEAEs, TRAEs, SAEs) and 6 more. Started Feb 2026; status: recruiting.
02
Drugs
AZD4512
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2031250707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250707.